2

Disclosures

Presentation Content

This presentation is private and confidential. No part of this presentation or the information contained herein may be reproduced, photocopied, redis-tributed or passed on, directly or indirectly, to any other person, or published, in whole or in part, for any purpose.

No Offer or Solicitation of Offer

This presentation is for informational purposes only. This presentation does not constitute an offer to sell or a solicitation of an offer to buy any secu-rities, nor shall it or any part of it, or the fact of its distribution, form the basis of or be relied on in any way in connection with any sale of securities. This presentation is directed only at persons for the purpose of business development.

Forward-Looking Statements

This presentation contains forward-looking statements that are subject to many risks and uncertainties. Forward looking statements include state-ments regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned product development; our intellectual property position; our ability to develop commercial functions; expectations regarding product launch and revenue; our results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which we operate; and the trends that may affect the industry or us. Although we believe we have a reasonable basis for each forward-looking statement, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity may differ materially from the forward-looking statements contained in this presentation.

Any forward-looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to up-date such statements to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events.

3

What is ieCrowd

A new way to invest in breakthrough health innovations while miti-gating some of the risks associated with early-stage investing.

4

Overview and Highlights

ieCrowd™ offers everyone an opportunity to invest in a group of breakthrough health innovations with big potential while miti-gating some of the risks associated with early-stage ventures.

ieCrowd has two innovations currently underway:

Kite: A breakthrough technology that makes people virtually invisible to mosqui-toes (revenue-producing)

Nuuma: A Nano electronic nose for smart devices (near revenue)

Raised $14M from angel investors, funds, strategic investors, family of-fices, and other investors worldwide.

Major customers have expressed interest in our innovations. Received let-ter of interest for an order valued at $20M+. Signed agreement with po-tential value of $80M+ over six years.

Have a pipeline of new innovations developed by major research institutions.

Experienced team committed to success.

5

6

Kite is a revolutionary technology platform designed to effective-ly protect against insects in a healthier way without using harsh chemicals harmful to people, animals, and the environment.

7

Discover

The Kite family of product candidates are built upon scientific break-throughs of understanding insect olfaction.

ieCrowd™ obtained rights to IP with an expert entomologist and a former pro-fessor at Vanderbilt University and UC Davis.

Kite’s proprietary NON-DEET formulas manipulate mosquitoes’ senso-ry detection system by confusing their carbon dioxide receptors, ma-king humans virtually invisible to them.

Kite’s proprietary formulas can be used in future product to control the behavior of other bloodseeking insects.

Kite products will be designed for use in multiple market segments – personal, home and garden, public health, companion animals, and vector and agricultural control.

8

Develop

Kite Shield is the first product based on Kite’s patent pending tech-nology. Kite Shield is a mosquito repellent spray proven effective against Culex quinquefasciatus, Aedes aegypti and Anopheles quadri-maculatus mosquitoes.

9

Develop

Development status:

Kite Shield’s proprietary formula of botanical active ingredients repels mosquitos for up to 4 hours.*

Completed 3rd-party efficacy test by Carroll-Loye Biological Re-search.

“The duration of repellency for Kite Shield is high for a product formulated from a palette of ingredients listed as minimum risk by the US Environmen-tal Protection Agency. These ingredients have not generally been combined to create effective repellent products.” - Carroll-Loye Biological Research

Kite Shield is exempt from Federal EPA registration requirements as it is considered to be “Minimum Risk Pesticide.”

Kite Shield is now registered with 49 state agencies.

Kite Shield is now in production.

*Up to 4 hours against Culex quinquefasciatus, 2 hours against Aedis aegypti, and 90 minutes against Anopheles quadrimaculatus mosquitoes.

10

Deploy

U.S. Distribution for Kite Shield:

Pre-sold $557,254 in Kite products in 2013 via Indiegogo.com.

Indiegogo InDemand campaign underway to sell Kite Shield.

DRTV campaign launching in 2016.

International distribution for Kite Shield:

Signed multi-year distribution agreement for all Kite products with YuYu Pharma, Inc.: Japan, South Korea, Singapore, Malaysia, In-donesia, Philippines.

In negotiation: Middle East and North Africa (MENA) representing 31 countries.

In discussion: Latin America.

Indiegogo campaign currently underway

We form partnerships with distribution partners from around the world in order to scale distribution.

11

Nuuma™ is a nanomaterials-based sensor that detects air-borne gases at the parts per billion level. Think of it as a “digi-tal nose.” Potential uses include mobile devices, smart city ap-plications, halitosis and more.

12

Discover

Patented and patent-pending nanomaterials-based sensor technologies for detecting airborne chemicals to the parts per-billion (ppb) level.

Designed to be embedded into mobile phones, wearable devices, and other existing and new technologies.

Potential uses include air quality monitoring, halitosis, preventing drunk driving, food and agricultural safety, security, explosives detec-tion, industrial plant toxic gas detection, gaseous chemical warfare

agent detection, and other applications.

Nuuma™ technology received $ 2.8 million in grant funding from the National Institute of Health (NIH), Center for Nanoscience Innovation for Defense (CNID) and other sources.

Patents: 7 granted; 2 pending. (Represented by Fenwick & West, LLP.)

ieCrowd™ obtained rights to the original IP

through its relationship with the UC Riverside.

13

Deploy

Mobile devices

In discussion with some of the top five mobile phone manufactur-ers to give phones the ability to smell.

Wearables

Received a Letter of Intent for 10M+ Nuuma chips to be integrat-ed into a wearable device produced by one of the largest manu-facturers.

Smart Cities

In negotiations and discussions to integrate Nuuma into smart parking meters to monitor air quality.

14

Deploy

Smart Homes

In discussion with one of the largest companies in the world to in-tegrate Nuuma™ into smart home devices for indoor air pollution, and smoke and fire detection.

Early Disease Detection

Currently collaborating with the Cancer Prevention Institute of California to advance the development of early detection technolo-gy for cancer, diabetes, Parkinson’s, and Alzheimer’s.

15

Our goal is to go public (full underwriting or through Reg. A+) in Q4, 2016 or early 2017 once certain business milestones are met.

Our Q3 2015 review and 2015 auditing is currently being com-pleted by Marcum, PCAOB registered independent public ac-counting and advisory services firm.

IPO: Planned Path to Liquidity